Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab in NSCLC after TKI failure
NCT01449357Phase 2Withdrawn
- Sponsor
- Genmab
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of zalutumumab in non-small cell lung cancer (NSCLC), sponsored by Genmab. Status: withdrawn.
02
Drugs
zalutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01449357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449357.